In a significant move addressing an escalating environmental and public health concern, HHS Secretary Robert F. Kennedy Jr. and EPA Administrator Lee Zeldin announced the Systematic Targeting of MicroPlastics (STOMP) program on April 2, 2026. This $144 million ARPA-H initiative aims to develop tools to measure, understand, and ultimately remove microplastics and nanoplastics from the human body, responding to mounting evidence of their accumulation in organs, blood, arterial plaques, brains, and even placentas. The program focuses on three key areas: creating affordable clinical tests for microplastic burden, mapping how these particles cross biological barriers and cause harm, and exploring safe removal methods through bioremediation and pharmaceutical approaches. This effort coincides with the EPA adding microplastics to the draft Contaminant Candidate List for drinking water, signaling potential future regulation. For years, research into microplastics' long-term effects on human health—including links to inflammation, reproductive disruption, and chronic disease—has been limited, despite widespread presence in food, water, and air. Corporate reliance on plastics and slow regulatory responses have contributed to what many see as an understudied crisis with generational population impacts, from fertility declines to neurological effects. By prioritizing measurement and intervention for vulnerable groups like pregnant women and children, STOMP could mark a turning point in shifting from industry minimization to proactive health protection. Official announcements emphasize that without reliable detection, effective policy and treatment remain impossible.